PAREXEL International Co. (NASDAQ:PRXL) was upgraded by equities researchers at Goldman Sachs Group Inc from a “sell” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday. The brokerage currently has a $77.00 price target on the medical research company’s stock, up from their previous price target of $63.00. Goldman Sachs Group Inc’s price objective would suggest a potential downside of 4.00% from the stock’s current price.

Several other research firms have also commented on PRXL. Barclays PLC restated an “overweight” rating and set a $87.00 price target on shares of PAREXEL International in a research report on Wednesday, May 17th. Zacks Investment Research upgraded shares of PAREXEL International from a “hold” rating to a “buy” rating and set a $78.00 price target on the stock in a research report on Thursday, January 26th. Evercore ISI upgraded shares of PAREXEL International from an “in-line” rating to an “outperform” rating and set a $85.00 price target on the stock in a research report on Monday, May 15th. Raymond James Financial, Inc. lowered shares of PAREXEL International from a “market perform” rating to an “underperform” rating in a research report on Thursday, February 2nd. Finally, Credit Suisse Group AG reiterated a “neutral” rating and issued a $65.00 target price (down previously from $68.00) on shares of PAREXEL International in a research report on Sunday, February 5th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $72.25.

Analyst Recommendations for PAREXEL International (NASDAQ:PRXL)

Shares of PAREXEL International (NASDAQ:PRXL) traded up 0.86% on Tuesday, reaching $80.21. 598,893 shares of the company traded hands. The stock has a market capitalization of $4.07 billion, a price-to-earnings ratio of 35.26 and a beta of 0.82. PAREXEL International has a 1-year low of $51.16 and a 1-year high of $81.79. The company has a 50-day moving average of $69.48 and a 200-day moving average of $65.58.

PAREXEL International (NASDAQ:PRXL) last released its quarterly earnings results on Wednesday, May 3rd. The medical research company reported $0.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The company had revenue of $529.30 million for the quarter, compared to analyst estimates of $529.38 million. PAREXEL International had a net margin of 6.34% and a return on equity of 29.92%. The firm’s revenue was up .4% on a year-over-year basis. During the same quarter last year, the business earned $0.89 earnings per share. Analysts anticipate that PAREXEL International will post $3.23 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/05/27/parexel-international-co-prxl-raised-to-neutral-at-goldman-sachs-group-inc.html.

In related news, SVP Sybrand Pretorius sold 8,050 shares of the business’s stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $65.12, for a total transaction of $524,216.00. Following the transaction, the senior vice president now directly owns 9,950 shares in the company, valued at $647,944. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.90% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its position in PAREXEL International by 22,876.6% in the first quarter. BlackRock Inc. now owns 5,513,456 shares of the medical research company’s stock worth $347,955,000 after buying an additional 5,489,460 shares during the last quarter. Credit Suisse AG raised its position in PAREXEL International by 1,897.2% in the first quarter. Credit Suisse AG now owns 2,093,297 shares of the medical research company’s stock worth $132,108,000 after buying an additional 1,988,488 shares during the last quarter. State Street Corp raised its position in PAREXEL International by 2.1% in the first quarter. State Street Corp now owns 1,673,118 shares of the medical research company’s stock worth $105,586,000 after buying an additional 34,328 shares during the last quarter. Nomura Holdings Inc. raised its position in PAREXEL International by 189.6% in the first quarter. Nomura Holdings Inc. now owns 1,381,087 shares of the medical research company’s stock worth $87,088,000 after buying an additional 904,236 shares during the last quarter. Finally, Congress Asset Management Co. MA raised its position in PAREXEL International by 6.9% in the first quarter. Congress Asset Management Co. MA now owns 814,555 shares of the medical research company’s stock worth $51,407,000 after buying an additional 52,925 shares during the last quarter. Hedge funds and other institutional investors own 91.44% of the company’s stock.

About PAREXEL International

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

12 Month Chart for NASDAQ:PRXL

Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with MarketBeat.com's FREE daily email newsletter.